The Biomic group has long experience on method development and validation for the determination of a wide range of pharmaceuticals and on the subsequent application in the analysis of several thousands of clinical samples. A list of developed protocols can be seen here.
Colistin
Doxycycline
Teicoplanin
Vancomycin
Cefuroxime
Ciprofroxacin
Daptomycin
Levofloxacin
Linezolid
Moxifloxacin
Tigecycline
2 Opioids
Cocaine and metabolites
12 Benzodiazepines
6 Ampthetamines
6 Barbiturates
Cannabis (THC, CBN, CBD)
TCA
10 NPS
Fentanyl
Ketamine
Lidocaine
Midazolam
Remifentanyl
Thiopental
Quetiapine
Olanzapine
Amisulpride
Haloperidol
Chlorpromazine
Levomepromazine
Nortriptyline
Venlafaxine
Citalopram
Fluoxetine
Bupropion
Mirtazapine
Sertraline
Phenobarbital
Clobazam
Lamotrigine
Phenytoin
Theophylline
Theobromine
Hypoxanthine
Cotinine
Xanthine
Nicotine
Hyoscyamine
Atropine
Scopolamine
Nicotine
cotinine
NNN
NNK
Fenitrothion
Parathion
m-parathion
Methomyl
Diazinon
Acetyl salicylic acid
Salicylic acid
Nimesulide
Niflumic acid
Mefenamic acid
Naproxen
Diclofenac
Ibuprofen
enkephalines
lisinopril
captopril
enalapril
Taxotere
Doxorubicin
Mitoxantrone
Ritonavir
Olmesartan
Irbesartan
Amphotericin B
phenylephrine
lacosamide
Octyl Salicylate
Octocrylene
Ethylhexyl methoxycinnamte
Diethylamino Hydroxybenzoyl Hexyl Benzonate
metformine
methylprednisolone
In the field of Pharmaceutical BioAnalysis and DMPK, BIOMIC_AUTH offers various possibilities for collaboration. Method development & validation can be performed for any xenobiotic for the analytical application in research or clinical studies. Substances of interest may include pharmaceuticals, natiral products, pesticides, or other drugs and metabolites.
The group works with scientists with specialization in Pharmacokinetics (PK) and have experience in the pharma industry.
Further to this Biomic is closely linked to the Centre for Special Unit for Biomedical Research and Education of the Medical School of AUTh. Biomic with its infrastructure and expertise supports the Clinical Trials Unit for the realization of phase I clinical trials, studies of bioequivalence and/or therapeutic equivalence. Drug monitoring deals with the measurement of pharmaceuticals and their metabolites in biological fluids, mainly blood. Its main focus is on drugs with a narrow therapeutic window. We aim at improving patient care by adjusting the dose of drugs or the drug regimen to assist clinicians in decision making to achieve improved clinical outcome.
ThetaBiomarkers is a spin-off launched by Biomic_AUTh staff, that is active on biomarker discovery, high quality analytical services and Research and Innonvation.